Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | MME | P08473 | 5/20 | 0.44 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674751 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL18613505 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL29425348 | 0.95 | ALDH1A1 (0.49) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL30974405 | 0.93 | MME (0.48) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL29663577 | 0.90 | ALDH1A1 (0.44) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL30808873 | 0.90 | ALDH1A1 (0.46) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL6367814 | 0.89 | OPRM1 (0.44) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL6367826 | 0.89 | OPRM1 (0.44) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL31289517 | 0.88 | MME (0.48) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL3873046 | 0.88 | ALDH1A1 (0.45) | ALDH1A1MEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661266-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Elcelyx Therapeutics, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | claimed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. | 2021-07-29 | — | — | US | disclosed |
| EP-3356356-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2661266-B1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ANJI PHARMA (US) LLC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2012054528-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20110177545-A1 | G-PROTEINS | GIVAUDAN SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-7919236-B2 | G-proteins | GIVAUDAN SA (CH) | 2011-04-05 | — | — | US | disclosed |
| EP-1581555-B1 | CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS | GIVAUDAN SA (CH) | 2008-04-30 | — | — | EP | disclosed |
| US-20060275765-A1 | G-proteins | GIVAUDAN SA (CH) | 2006-12-07 | — | — | US | disclosed |
| EP-1581555-A2 | G-PROTEINS | Givaudan SA (CH) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004055048-A2 | CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS | GIVAUDAN SA (CH) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | ALDH1A1 978/4885MEN1 2644/4885LMNA 4834/4885 |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALDH1A1 764/4885MEN1 1559/4885LMNA 3720/4885 |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | ALDH1A1 764/4885MEN1 1559/4885LMNA 3720/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | ALDH1A1 978/4885MEN1 2644/4885LMNA 4834/4885 |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | ALDH1A1 978/4885MEN1 2644/4885LMNA 4834/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | ALDH1A1 978/4885MEN1 2644/4885LMNA 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.